Annals of Neurology · 2000 · 3.3K citations · 42 references
Life SciencesNeurologyPathologyAutoimmunityImmunopathologyNeuroimmunologyAutoimmune DiseasesAutoimmune Neurological DisordersDemyelinating DiseasesDemyelinating DisordersNervous System PathologyNeuroinflammationDemyelinating PlaquesImmune-mediated DemyelinationImmunopathological MechanismsInflammatory DemyelinationMultiple Sclerosis ImmunopathogenesisMultiple Sclerosis ImmunopathologyMultiple Sclerosis PathologyNeurobiological Markers
Multiple sclerosis (MS) is a disease with profound heterogeneity in clinical course, neuroradiological appearance of the lesions, involvement of susceptibility gene loci, and response to therapy. These features are supported by experimental evidence, which demonstrates that fundamentally different processes, such as autoimmunity or virus infection, may induce MS-like inflammatory demyelinating plaques and suggest that MS may be a disease with heterogeneous pathogenetic mechanisms. From a large pathology sample of MS, collected in three international centers, we selected 51 biopsies and 32 autopsies that contained actively demyelinating lesions defined by stringent criteria. The pathology of the lesions was analyzed using a broad spectrum of immunological and neurobiological markers. Four fundamentally different patterns of demyelination were found, defined on the basis of myelin protein loss, the geography and extension of plaques, the patterns of oligodendrocyte destruction, and the immunopathological evidence of complement activation. Two patterns (I and II) showed close similarities to T-cell-mediated or T-cell plus antibody-mediated autoimmune encephalomyelitis, respectively. The other patterns (III and IV) were highly suggestive of a primary oligodendrocyte dystrophy, reminiscent of virus- or toxin-induced demyelination rather than autoimmunity. At a given time point of the disease--as reflected in autopsy cases--the patterns of demyelination were heterogeneous between patients, but were homogenous within multiple active lesions from the same patient. This pathogenetic heterogeneity of plaques from different MS patients may have fundamental implications for the diagnosis and therapy of this disease.
42
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Charles M. Poser, Donald W. Paty, Labe C. Scheinberg et al. · Annals of Neurology · 1983 · 7.4K citations
Identification of autoantibodies associated with myelin damage in multiple sclerosis
Claude P. Genain, Barbara Cannella, Stephen L. Hauser et al. · Nature Medicine · 1999 · 890 citations
Life Sciences, Immunology, Neurology +14
Tumor necrosis factor identified in multiple sclerosis brain.
Florence M. Hofman, David R. Hinton, K. P. Johnson et al. · The Journal of Experimental Medicine · 1989 · 799 citations
Christopher Linington, Monika Bradl, Hans Lassmann et al. · PubMed · 1988 · 721 citations